Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) and Cassava Sciences (NASDAQ:SAVA – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.
Volatility & Risk
Reviva Pharmaceuticals has a beta of -0.02, indicating that its stock price is 102% less volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -1.08, indicating that its stock price is 208% less volatile than the S&P 500.
Institutional & Insider Ownership
63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are held by institutional investors. 8.9% of Reviva Pharmaceuticals shares are held by insiders. Comparatively, 12.2% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Reviva Pharmaceuticals | 1 | 0 | 7 | 1 | 2.89 |
| Cassava Sciences | 1 | 1 | 0 | 0 | 1.50 |
Reviva Pharmaceuticals currently has a consensus price target of $3.86, suggesting a potential upside of 1,229.13%. Cassava Sciences has a consensus price target of $2.00, suggesting a potential downside of 4.31%. Given Reviva Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Reviva Pharmaceuticals is more favorable than Cassava Sciences.
Profitability
This table compares Reviva Pharmaceuticals and Cassava Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Reviva Pharmaceuticals | N/A | -20,501.80% | -187.50% |
| Cassava Sciences | N/A | -63.39% | -49.81% |
Valuation and Earnings
This table compares Reviva Pharmaceuticals and Cassava Sciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Reviva Pharmaceuticals | N/A | N/A | -$29.92 million | ($0.46) | -0.63 |
| Cassava Sciences | N/A | N/A | -$24.34 million | ($2.19) | -0.95 |
Cassava Sciences is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Reviva Pharmaceuticals beats Cassava Sciences on 8 of the 12 factors compared between the two stocks.
About Reviva Pharmaceuticals
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.
About Cassava Sciences
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Receive News & Ratings for Reviva Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reviva Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
